

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 December 2024 (12.12.2024)



(10) International Publication Number
WO 2024/254190 A3

(51) International Patent Classification:

C07D 317/46 (2006.01) A61P 19/00 (2006.01)
A61K 31/36 (2006.01) A61P 25/24 (2006.01)
A61P 21/00 (2006.01) A61P 25/04 (2006.01)

(21) International Application Number:

PCT/US2024/032615

(22) International Filing Date:

05 June 2024 (05.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/471,412	06 June 2023 (06.06.2023)	US
63/602,904	27 November 2023 (27.11.2023)	US
63/605,729	04 December 2023 (04.12.2023)	US
63/607,702	08 December 2023 (08.12.2023)	US
63/553,788	15 February 2024 (15.02.2024)	US
63/649,653	20 May 2024 (20.05.2024)	US

(71) Applicant: **TRANSCEND THERAPEUTICS, INC.**
[US/US]: 80 5th Avenue, Floor 18, New York, New York
10011 (US).


(72) Inventors: **MANDELL, Blake**; 863 Carroll Street, Apt 1B,
Brooklyn, New York 11215 (US). **STOGNIEW, Martin**;
7811 Mathern Ct, Lakewood Ranch, Florida 34202 (US).
SCHMIDT, Jennifer Louise; 45 Harvard St, Garden City,
New York 11530 (US). **SEELIG, Markus**; 4665 Hawaina
Way, Kelseyville, California 95451 (US).

(74) Agent: **PASSNER, Jonathan M.**; 7 Times Square, 19th
Floor, New York, New York 10036 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL
CONDITIONS AND DISORDERS

Figure 21



* p < 0.05; ** p < 0.001; *** p < 0.0001

(57) Abstract: The invention relates to psychoactive medicines including methylone, 2C-B, MBDB, their respective salts, metabolites, isomers, enantiomers, solvates, isotopologues and isotopomers, polymorphs, prodrugs and analogs (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(88) Date of publication of the international search report:

17 April 2025 (17.04.2025)